News | February 13, 2021
Jubilant Pharmova recovers: ICICI Securities
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.
The partnership is a significant step in delivering advanced cancer therapies to patients.
The company has reported total income of Rs.25699.68 crores during the 9 months period ended December 31, 2020.
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.
Lasa Supergenerics Limited has received WHO GMP Certificate for its manufacturing facility situated at Khed in Ratnagiri.
Subscribe To Our Newsletter & Stay Updated
